Sun Pharmaceutical Industries: Checkpoint Acquisition to Strengthen Specialty Business
Sun Pharma (SUNP) and Checkpoint Therapeutics Inc (Checkpoint) have entered into an agreement under which SUNP will acquire Checkpoint, an...
348 Views
Sun Pharmaceutical Industries: Specialty and Domestic Formulation to Drive Growth.
Sun Pharma (SUNP) is expected to sustain steady growth momentum, driven by strong traction in its global specialty business (18% of sales)
541 Views
Sun Pharma - Addressing the Oral IL-23 Antagonist Challenge to Ilumya
Emkay Global Financial's research report on Sun Pharma J&J, in a recent investor interaction, had stated that its oral IL-23 receptor antagonist...
254 Views
Sun Pharma - ‘Specialty’ Way of Driving Growth Prospects
The overall R&D expenditure is expected to increase by 33% YoY in FY24 and maintain an 18% CAGR over FY24-26 to support clinical development of...
302 Views
Sun Pharmaceutical Industries: SUNP’s Subsidiary Taro Posts Strong Performance.
Taro posted strong sales growth of 13% YoY to USD 157 mn (+6% QoQ), led by new launches with a sharp improvement in adjusted EBITDA to USD 24 mn
291 Views